Physician downloads
Dezawa Muse Cell Clinical Library
The official reference set for clinicians evaluating authentic Dezawa MuseCell®–derived biologics — comparison tables, the aesthetic medicine white paper, and the clinician education series covering science, manufacturing, handling, dosing, and precautions.
Download the source materials
Comparison sheet
Dezawa MuseCells® vs Traditional MSCs
One-page comparison table — differentiable cell types, in-vivo differentiation, homing after IV infusion, immune rejection, survival in target organ, and more.
Download →
Comparison sheet
Dezawa MuseExosomes® vs Traditional Exosomes
Side-by-side of biological activity, targeted homing, regenerative potential across germ layers, stress resistance, and immune compatibility.
Download →
White paper
Dezawa Aesthetics™ Clinical White Paper
Full peer-reviewed white paper for plastic surgeons, dermatologists, and aesthetic medicine specialists — mechanism, evidence, applications, and implementation.
Download →
Product sheet
Dezawa Aesthetics™ Kit Overview
Product overview covering the 5×lyophilized MuseExosomes® + 5×HA diluent kit, rejuvenation benefits, and preparation.
Download →
Clinician education
Dezawa MuseCell® Clinician Education Series
In-depth clinician education: science, manufacturing, handling, application, dosing, secretome vs cellular vs exosome selection, and clinical precautions.
Download →
The three pillars of Dezawa MuseCells®
Distilled from the clinician education series — what differentiates authentic Dezawa MuseCells® from conventional MSCs and other pluripotent platforms.
Pluripotency without teratoma risk
Differentiate into virtually any cell type spontaneously in vivo, without genetic engineering — while low telomerase activity and the Let-7/Lin28 axis keep oncogenic targets suppressed.
S1P–S1PR2 homing
Actively seek out injured tissue by following sphingosine-1-phosphate, making intravenous delivery a precision targeting mechanism rather than a delivery limitation.
Immune privilege
HLA-G expression and immunomodulatory factors enable allogeneic use without HLA matching or immunosuppression.
Dezawa MuseCells® vs traditional MSCs
Traditional MSCs may cause stronger immune responses — leading to more rejection, swelling, and inflammation, and in up to 15% of patients trigger antibodies after multiple treatments. Dezawa MuseCells® survive longer in tissue, calm inflammation more effectively, and usually don’t require donor matching.
| Dezawa MuseCells® | Traditional MSCs | |
|---|---|---|
| Differentiable cell types | Most cell types in the body | Osteocytes, chondrocytes, adipocytes |
| Differentiation in vivo | Yes | Very low rate, if any |
| Tumorigenicity | None | None |
| Immune rejection (donor cells) | None | Lesser extent |
| Immunosuppressant treatment | Not necessary | Case-by-case |
| Best delivery route | Intravenous infusion | Local injection |
| Delivery to target organ after IV | ~15% | Less than 1%, if any |
| Replacement by differentiation | Yes | No |
| Angiogenesis | Yes | No |
| Survival in target organ | Longer than several years | No |
| Gene manipulation required | No | No |
Source: MuseCell Innovations® — Dezawa MuseCells® vs Traditional MSCs comparison sheet.
Dezawa MuseExosomes® vs traditional exosomes
| Dezawa MuseExosomes® | Traditional exosomes | |
|---|---|---|
| Biological activity & stability | Enhanced stability; more resistant to degradation, retains activity longer in circulation. | Shorter functional half-life, typically cleared within hours to days. |
| Targeted homing | Actively home to damaged tissue via specific surface markers. | Passive distribution with no innate targeting ability. |
| Regenerative potential | Pluripotent-like — signals influence all three germ layers (ecto-, meso-, endoderm). | Restricted to mesodermal-derived tissue (bone, muscle, cartilage, connective). |
| Stress resistance | Survive and function under oxidative and inflammatory stress. | Sensitive to environmental stress; requires strict storage. |
| Immune compatibility | Low immunogenicity and hypoimmunity — superior clinical safety. | Higher immunogenicity risk in allogeneic applications. |
Source: MuseCell Innovations® — Dezawa MuseExosomes® vs Traditional Exosomes comparison sheet.
Dezawa Aesthetics™ — the aesthetic medicine platform
A three-tier regenerative portfolio built for plastic surgeons, dermatologists, and aesthetic medicine specialists: Dezawa MuseCells® (cellular substrate), Dezawa MuseExosomes® (lyophilized extracellular vesicles from authenticated Muse cultures), and Dezawa MuseSecretome® (conditioned-medium bioactive complex with the full Muse-secreted growth factor, cytokine, and microRNA repertoire).
Rejuvenation benefits
Improves texture, tone, and elasticity; reduces fine lines, scarring, and surface irregularities; enhances hydration and barrier function; promotes healthier collagen architecture; calms inflammation.
The kit
5× lyophilized Dezawa MuseExosomes® (60 mg each) paired with 5× medical-grade Hyaluronic Acid diluent (3 mL each). Prepared immediately before treatment for maximum vitality.
Clinical applications
Microneedling and fractional energy-based protocols, scar revision, alopecia and scalp regeneration, post-surgical recovery, and combined regenerative skin rejuvenation.
Five axes of differentiation
Defined SSEA-3⁺ source population, stress-tolerant cargo profile, integrated three-tier portfolio, authenticated manufacturing lineage, and rigorous certificate-of-analysis documentation.
Authentication checklist for clinicians
- Source exclusively through an MCI-authorized supply partner.
- Require lot-level documentation confirming ≥70% SSEA-3⁺ purity and 80–90%+ cell viability on the certificate of analysis.
- Confirm the SSEA-3 antibody lot used in manufacturing (e.g., BioLegend #330302 or Thermo Fisher MA1-020) — lot-to-lot consistency directly affects purity.
- Do not administer preparations from unauthorized suppliers or beyond passage P=10.
- Document lot number, passage, viability at time of infusion, route, and dose to support pharmacovigilance and outcomes tracking.
Bring these protocols into your practice
Watch the Summit talks from the physicians pioneering these therapies, or request information about bringing MuseCells, MuseExosomes, and regenerative peptides into your clinic.